Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections

INTRODUCTION: The effect of tixagevimab/cilgavimab (Evusheld™; AstraZeneca, UK) should be evaluated in the context of concurrent outbreak situations. METHODS: For serologic investigation of tixagevimab/cilgavimab during the BA.5 outbreak period, sera of immunocompromised (IC) hosts sampled before an...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jinyoung, Won, Gunho, Baek, Jin Yang, Lee, Young Ho, Kim, Haein, Huh, Kyungmin, Cho, Sun Young, Kang, Cheol-In, Chung, Doo Ryeon, Peck, Kyong Ran, Lee, Kyo Won, Park, Jae Berm, Yoon, Sang Eun, Kim, Seok Jin, Kim, Won Seog, Yim, Min Su, Kim, Kwangwook, Hyeon, Seokhwan, Kim, Byung Chul, Lee, Yoo-kyung, Ko, Jae-Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017459/
https://www.ncbi.nlm.nih.gov/pubmed/36936968
http://dx.doi.org/10.3389/fimmu.2023.1139980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017459/
https://www.ncbi.nlm.nih.gov/pubmed/36936968
http://dx.doi.org/10.3389/fimmu.2023.1139980

Ejemplares similares